anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Bone marrow (BM) is the major organ where immune cells are derived. Homeostasis in the BM is maintained by inter- and intra-cellular interactions by the various subsets of BM cells. The present invention discloses the cloning of a new cDNA from stimulated BM stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The cloned cDNA was designated ‘Hematopoietic Growth Factor Inducible Neurokinin-1 type’ (HGFIN) gene based on its expression in differentiated hematopoietic cells. Hence, the present invention provides a novel gene, HGFIN, which encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. The protein of the present invention may be involved as a central mediator of white blood cell, progenitor, differentiation, and therefore, may be useful in the prevention and treatment of lymphoproliferative syndromes such as B-cell related maladies, including but not limited to acute and chronic myeloid and lymphocytic leukemia as well as the B-cell subtype of Hodgkin&#39;s and non-Hodgkin&#39;s lymphomas.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a nonhemolytic new microorganism immediately starting its logarithmic growth with no lag phase at all, in spite of a fact that, in general, when bacteria are put on a new environment (medium), there are several hours of such a lag phase, called a growth preparatory period, prior to starting the growth.  &lt;P&gt;SOLUTION: The new microorganism is Bacillus sp. OYK-01-600 (FERM BP-6394), Bacillus sp. OYK-03-600 (FERM BP-6395) or Bacillus sp. OYK-04-000 (FERM BP-6396). Its characteristic is that, during its logarithmic growth, there are several hours of a period in which other bacteria grow little, and for this period, the number of the OYK bacteria comes several ten-thousand-fold the other bacteria. While the OYK bacteria, in themselves, exhibit antibacterial activity on harmful bacteria (e.g. Staphylococcus aureus including methicillin-resistant Staphylococcus aureus), the OYK bacteria inhibits offensive-odor-generating bacteria and various harmful infectious bacteria owing to the growth speed difference.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To prepare a bleaching cosmetic having high bleaching effect and safety to the skin, and easily producible at a low cost.  &lt;P&gt;SOLUTION: This bleaching cosmetic contains powder obtained by grinding or crushing paddy and oil consisting of olive oil, camellia oil or rice oil. The cosmetic has high bleaching effect since skin aging phenomena including pigmentation and wrinkles can be prevented by active oxygen scavenging function, antioxidant function and radical scavenging function, or the like, each inherent in paddy. The paddy powder is a natural material, thus being highly safe to the skin. Because of using the paddy powder, this cosmetic can easily produced at the low cost. Further, the oil is rich in oleic acid of the above oils, therefore this cosmetic has high storage stability and heating stability.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
A smart mat system is provided for performing exercises herein. The smart mat system may include an exercise mat. The exercise mat may include sensors configured for sensing objects. The sensors may transmit sensor information to a mobile component. The mobile component may determine a user&#39;s balance, weight distribution, and correctness of a pose. The mobile component may store historic data associated with the user&#39;s exercises.
PURPOSE:To separate and purify easily and efficiently glycyrrhizin, by bringing an extract solution of a licorice into contact with a synthetic resin adsorbent, weakly adsorbing the glycyrrhizin on the synthetic resin, strengthening the adsorption by treatment with an acid, washing the adsorbed glycyrrhizin with water, and eluting the glycyrrhizin with an organic solvent. CONSTITUTION:An extract solution of a licorice containing glycyrrhizin is brought into contact with a medium polar or nonpolar synthetic resin adsorbant having the giant network structure under warming preferably at 50-60 deg.C to adsorb weakly the glycyrrhizin on the synthetic resin adsorbent. The adsorbent is then treated with an inorganic or organic acid to strengthen the adsorption of the glycyrrhizin. The adsorbent is then washed with water to flow out impurities and the acid used in the above-mentioned step. The adsorbed glycyrrhizin is then eluted with a hydrous organic solvent or organic solvent. A styrene-divinylbenzene type polymer having 250-800m&lt;2&gt;/g specific surface area, 40-100Angstrom  average pore diameter and 30-55vol% porosity may be cited as the above-mentioned nonpolar adsorbent.
This disclosure relates to analyzing effect of a secondary cognitive load task on a primary executive task. Human random sequence generation is a marker to study cognitive functions and inability to generate random sequences (RS) can reveal underlying impairments. Traditionally, &#39;call out&#39; or &#39;write down&#39; procedures are used to obtain human generated numbers, wherein short term memory and number of previously generated entities visible to a subject plays a major role. Also precise trial-wise or response-wise analysis may not be possible. In the present disclosure, the human generated random numbers are digitized into RS and a cognitive load (CL) inducing task is imposed on the executive task. The CL demanding task disrupts randomization performance. Deviation from randomness, load index based on gaze data and deviation from pupillometry data of healthy subjects are provided as indicators of an interference effect imposed by the CL and thereby indicative of underlying impairments.
PURPOSE:To prevent the absorption of UV in the skin by incorporating a specified benzophenone deriv. into silica-based spherical fine particles of 0.1-30mum average particle size to form microcapsules. CONSTITUTION:A benzophenone deriv. represented by formula I (where each of X and Y is 1-24C alkyl, alkoxy, sulfonic acid or alkali metal sulfonate, each of m and n is an integer of 0-3 and each of k and l is an integer of 1-4) is dissolved in an aq. soln. of alkali metal silicate. This aq. soln. is mixed with an org. solvent having &lt;=5% solubility in the benzophenone deriv. and water to prepare a W/O type emulsion and an acidic aq. soln. is mixed with the emulsion. The benzophenone deriv. is then incorporated into silica-based spherical fine particles of 0.1-30mum average particle size to produce microcapsules contg. an UV absorber.
PURPOSE:To produce a material containing immobilized enzyme having high strength to endure the industrial use, by freezing a mixture of a specific aqueous solution of PVA, an enzyme-containing composition and boric acid in a vessel, and drying the formed mixture. CONSTITUTION:An aqueous solution of a polyvinyl alcohol having a saponification degree of &gt;=95mol% and an average polymerization degree of &gt;=1,000 is mixed homogeneously with an enzyme-containing material and boron or borax. The mixture is frozen in a vessel having an arbitrary form at &lt;=-6 deg.C, and the obtained formed product is dried spontaneously or under aeration. The concentration of the aqueous solution of polyvinyl alcohol is 5-30W/W%, preferably 10-20W/W%. When the concentration is low, the mechanical strength of the obtained material containing immobilized enzyme becomes poor, and when the concentration is too high, the preparation is difficult because of the solubility of the polyvinyl alcohol. The enzyme-containing material means an enzymatic agent or an enzyme-producing microbial cell.
PURPOSE:To provide the titled suppository having high stability and containing a macrogol solid at normal temperature, a fatty acid glyceride solid at normal temperature, a surfactant and an agent for promoting precipitation of indomethacin. CONSTITUTION:The objective indomethancin suppository can be produced by mixing (A) 10-80wt% macrogol which is solid at normal temperature (e.g. having a molecular weight of &gt;=1,000) and a fatty acid glyceride which is solid at normal temperature (e.g. 12-18C fatty acid triglyceride), (B) 0.5-2wt% surfactant (e.g. polyoxyethylene polyoxypropylene glycol) and (C) an agent for promoting the precipitationof indomethancin (e.g. a polyhydric alcohol such as glycerol, a sucrose fatty acid ester, a substance forming a precipitation nucleus such as NaCl) with (D) indomethacin under melting and cooling and solidifying the molten base, thereby precipitating indomethacin from the mixture. It is preferable to use a polyhydric alcohol in combination with a sucrose fatty acid ester to promote the precipitation of indomethacin in the base.
PURPOSE:The titled plaster base capable of keeping a blended drug stably without decomposing it, obtained by adding an oxyanthraquinone compound to rubber-like adherent substance. CONSTITUTION:A plaster base consisting of a rubber-like adherent substance of natural rubber or synthetic rubber or their mixture is blended with an oxyanthraquinone compound such as a compound shown by the formula (R&lt;1&gt; is lower alkyl, hydroxymethyl, or carboxyl; R&lt;2&gt; is H, OH, or lower alkoxy). A natural compound is preferable as the compound shown by the formula, chrysophanol, emodin, rhein, etc. may be cited as it, and plants containing them are used in the form of extracts too. A preferable amount of the compound shown by the formula blended is 0.02-2wt% based on the adherent substance, an amount of plant containing it is 0.02-5wt%, and an amount of plant extract is 0.005- 4wt%. It is especially effective for drugs consisting of phenolic hydrogyl group- containing compounds or amine compounds, which are extremely decomposed with a common plaster base.
The present invention relates to the treatment of myopathy. The inventors report the identification of effective AS-siRNA against the two nucleotide versions of the two non- pathogenic DNM2 SNPs which may be used to silence any mutation carried by the same mRNA. In addition, the first AS-siRNAs targeting a DNM2 mutation associated with severe neonatal phenotype, i.e. the p.S619L mutation, have been developed and in a second time, they developed other AS-siRNA targeting the mutation p.S619L and the mutation p.R465W. They also report the functional benefits of this new set of siRNAs on several defects identified in patient-derived cell lines. The development of these new AS-siRNA, in addition to the previous ones against the p.R465W mutation, provides a panoply of allele-specific molecules able to target the large majority of AD-CNM patients. Interestingly, siRNAs against the DNM2 SNPs represent versatile molecules with larger potential applications to silence DNM2 mutations in CMT and HSP and to reduce DNM2 expression in a controlled manner in diseases associated with deleterious overexpression. Thus, the present invention relates to an allele specific siRNA (AS-siRNA) able to silence the expression of only one allele of a heterozygous DNM2 gene wherein the targeted allele comprises a non-pathological polymorphism selected from the group consisting of rs2229920 (C or T) or rs12461992 (A or T) and/or a disease-causing mutation selected from the group consisting of c.1393C&gt;T or c.1856C&gt;T.
&lt;P&gt;PROBLEM TO BE SOLVED: To efficiently utilize crustaceans, especially krill, as resources, to efficiently recover fat-soluble effective substances, such as carotenoid, highly unsaturated fatty acid, and phospholipid, which are components of the crustaceans, and to utilize the substances.  &lt;P&gt;SOLUTION: An aggregate is formed by collecting eyeballs of the crustaceans, so that the aggregate is used as a supply source of the carotenoid, the highly unsaturated fatty acid, and/or the phospholipid. A food or a dietary supplement contains the collected eyeballs, as they are, or a powdered product thereof and is used for supplying the carotenoid, the highly unsaturated fatty acid, and/or the phospholipid. The aggregate is produced by reducing a water content of the crustaceans to make the eyeballs bring into a state of being easily separated, and then giving physical impact thereto, so that the eyeballs are isolated and recovered. The krill or mysids are preferably used as the crustaceans.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A digital pillbox, a personal alert device, and a computer-implemented system and method for aiding a patient in maintaining a desirable dosage schedule of medicines. Sensors and logic determine a time and quantity of a dosage taken, if any, and the system keeps records and monitors against a schedule and against a dynamic, learning, behavioral model of the patient. The schedule is remotely updateable by e.g. the patient&#39;s pharmacist. The system is equipped to alert e.g. a friend of the patient, or emergency services, if the patient fails to take the desired medications or if the patient&#39;s dosage behavior exhibits a significant change.
PROBLEM TO BE SOLVED: To obtain a diabetes diagnostic effective even if intended for patients with light diabetes, slight in burden on subjects, and instantaneously affording an accurate test result, by including a specific fatty acid. SOLUTION: This diagnostic is obtained by including a fatty acid with at least one carbon atom on specific site labeled with&lt;13&gt; C; wherein the fatty acid is pref. acetic acid, octanoic acid, palmitic acid, oleic acid, linoleic acid, linolenic acid. The test using this diagnostic is such an exhalation test that a subject is administered with this diagnostic either singly or continually, and an increment in the&lt;13&gt; C concentration of exhaled CO2 after the administration is determined. Specifically, the&lt;13&gt; C concentration of the exhaled CO2 following administration is measured, and the aimed diagnosis of diabetes is conducted on the basis of data such as the increment in the&lt;13&gt; C concentration of exhaled CO2 [Δ&lt;13&gt; (%)] after the lapse of a given time following the administration (e.g. 5 min, 10 min, 15 min).
The invention relates to a traditional Chinese medicine composition for treating cancer and a cocktail therapy thereof. The composition is a medicament prepared by the following bulk drugs according to parts by weight: 5 parts of corydalis tuber, 6 parts of rhodiola root, 9 parts of leech, 9 parts of centipede, 9 parts of sanguisorba, 9 parts of trametes robiniphila murr, 3 parts of giant knotweed, 3 parts of Herba Lycopi, 7 parts of radix bupleuri, 4 parts of selfheal and 2 parts of Clematis chinensis. The invention also relates to a preparation method for adding the composition in cocktail to be brewed and then administrated, commonly referred to as &#39;cokctail therapy&#39;. The composition has functions of inhibiting tumor cells, reducing obstruction and eliminating stagnation, stimulating the menstrual flow and removing stasis, promoting blood circulation, strengthening immune function, getting rid of the stale and bringing forth the fresh, building body, keeping health and the like. What is more, the &#39;cocktail therapy&#39; is unique and marked in effect. The traditional Chinese medicine composition has good healing effect especially on lung cancer, liver cancer and esophagus cancer.
An implant, adapted for insertion in a mammalian body cavity, for use in selectively removing from a body fluid and immobilising on the implant at least one known target, where the implant comprises a biologically compatible substrate comprising a surface layer comprising a ligand which binds a moiety which specifically binds to the target. Methods of making and using the implant are also claimed. The ligand is preferably streptavidin/avidin or biotin which binds to the other member of the binding pair linked to an antibody. Examples describe the use of biotinylated CD20 antibodies which bind to B- cells. The implant may also release pharmaceuticals eg antibacterial, antineoplastic, antithrombotic or anti-viral drugs. Preferably, the device is a stent for immobilising and removing B-lymphocytes from the blood of non-Hodgkin&#39;s lymphoma patients.
A CT Fluoro System display which includes apparatus and methods for facilitating effective performance of an interventional procedure. The apparatus and methods are generally referred to herein as partial image display, dynamic image reformation, in-room control, flat panel display, in-room display, and magnification. More particularly, an important performance parameter for a CT Fluoro System is the time to first image. Accordingly, and to reduce the time to first image, a partially reconstructed image can be displayed. In addition to fast image reconstruction, it sometimes is necessary to examine a needle position from different orientations, i.e., views. Accordingly, the present display provides dynamic image reformation wherein axial images are displayed at a very high rate and the operator may reformat the axial images and display the reformatted images in real time. Further, and to provide additional functionality and convenience for an operator, an in-room, or convenient, control including a &#34;reverse and forward&#34; play command button, &#34;save&#34; (or capture), &#34;grid display&#34;, and &#34;preset window/levels&#34; functions is provided. By enabling an operator to perform these functions with the remote unit, the system is believed to be easier to use and useful information to the operator in an easily understandable format. Also, and to provide improved display, a flat panel display may be utilized. A user interface for use with the display includes a CT/i Interventional control, three message areas (hierarchical and designated as message area #1, message area #2, and message area #3), and an image control. Also, image magnification can be performed.
FIELD: medicine, phytotherapy, pharmacy. SUBSTANCE: invention relates to the development of agents of vegetable origin. Invention proposes a novel medicinal agent &#34;PATRIMIN&#34; showing sedative, hypotensive, anticoagulating, antiaggregating and hypolipidemic effects. An agent presents the dried extract of triterpene glycosides-patrinosides D, B and C prepared from median patrinia roots (Patrinia intermedia (Horn.) Roem et Schult) where the content of oleonic acid is 10-19% per absolutely dried extract. Low toxicity and broad range of activity of the preparation show an advantage in medicinal practice as compared with narrow-pattern drugs (valerian, motherwort tinctures and others). EFFECT: new agent indicated above, valuable medicinal properties. 1 cl
The invention discloses rose essential oil eye repairing and tightening essence and a preparation method thereof. Belongs to the technical field of cosmetics. The composite material comprises the following components in percentage by mass: 3-5% of rose essential oil, 20-35% of rose hydrosol, 5-6% of a humectant, 1.5-2% of a whitening component, 0.1-0.2% of a soothing and anti-allergy component, 1.5-2% of a natural antioxidant, 0.15-0.2% of a natural preservative, 0.4-0.6% of a natural emulsifier and the balance of deionized water. The invention takes rose essential oil and rose hydrosol as effective components, and adds a plurality of natural components and other components which promote permeation and absorption to interact with the effective components to prepare the eye-repairing and tightening essence. Easy absorption, safety and no irritation. The product has effects of moistening, tightening and smoothing eye skin, and can also relieve black eye, pouch, crow&#39;s feet, and fat granules.
A system and related method for remotely monitoring the health of a patient are provided to inform the patient as to his/her state of health. Data on a patient physiological parameter is analyzed at a patient site using Shewhart&#39;s rules of detection. The patient is notified when the conditions for one of Shewhart&#39;s rules are met, which may indicate a significant change in the patient&#39;s health status. Preferably, the notice to the patient is tailored by the patient&#39;s health care provider, and may instruct the patient to contact the health care provider or take some other preventative action. Preferably, information is transferred from the patient site to a health care provider site. An elementary system has a patient operated sensor for taking physiological measurements and converting them into an indexed data record, a patient site data processing unit with a database for storing such indexed data records, and a SPC instruction set which enables the patient site data processing unit to perform a SPC analysis on the indexed data records to determine if Shewhart&#39;s rules are met. Means for notifying the patient that one of Shewhart&#39;s rules is met are also provided.
The present invention relates to liposomes for drug delivery, wherein a liposome comprises molecules of at least one desired drug distributed within an aqueous phase in the interior of the liposome and wherein the liposome further comprises molecules of the same or of another drug attached to either or both sides of the liposomal membrane. More specifically, the invention relates to liposomes, wherein at least a part of the molecules of a desired drug bear a functional group that is reactive with a functional group present in at least one lipid fraction, and wherein the drug is covalently linked to the membrane lipids by chemical bonding, e.g. by ester bonding of a hydroxyl group of a lipid molecule and an acidic residue of the drug. In a preferred embodiment, the desired drug is a glycoprotein such as erythropoietin. The invention further relates to a method of manufacture of said liposomes and to pharmaceutical compositions containing them. ® KIPO &amp; WIPO 2007
PCT No. PCT/KR91/00012 Sec. 371 Date Feb. 26, 1992 Sec. 102(e) Date Feb. 26, 1992 PCT Filed Apr. 19, 1991 PCT Pub. No. WO92/00981 PCT Pub. Date Jan. 23, 1992.The present invention relates to novel cephalosporins of the formula (I);    &lt;IMAGE&gt;  (I)  wherein, R1 represents a C1 DIFFERENCE C4 alkyl group or   &lt;IMAGE&gt;    wherein, R2 and R3, independently, represent hydrogen or a C1 DIFFERENCE C3 alkyl group and R4 represents hydrogen or a C1 DIFFERENCE C4 alkyl group; R1a represents hydrogen or an amino-protecting group; Q represents CH or N; and the formula   &lt;IMAGE&gt;    represents a saturated or unsaturated heterocyclic group which contains 1 to 4 nitrogen atoms of which one is substituted with an amino group to form quaternary ammonium, and oxygen or sulfur, or a fused heterocyclic group thereof formed together with a substituted or unsubstituted benzene or an optional heterocyclic group, or a pharmaceutically acceptable salt thereof, to processes for preparing the same and to a pharmaceutical composition containing the same as an active ingredient. The compounds(1) according to the invention exhibit potent antibacterial activity and broad antibacterial spectrum against the Gram-positive strains including Staphylococcus as well as Gram-negative strains including Pseudomonas, and, therefore, are expected to be very useful in treatment of various diseases caused by bacterial infection in human beings and animals.
PURPOSE:To provide a carcinostatic agent having proliferation suppressing effect to various tumors, by extracting dragon&#39;s blood with water or an organic solvent miscible freely with water, and using the extract as an active component. CONSTITUTION:Dragon&#39;s blood (rosin obtained from the fruit of Daemonorop draco) is extracted with water and/or an organic solvent miscible freely with water (e.g. methanol), and the extract is used as an active component of a carcinostatic agent. Dragon&#39;s blood contains a red pigment dracorubin (C32H24O5), and has been used as a stegnotic for antidiarrhetic or hemostatic use for a long time, and it has been newly found that the substance exhibits excellent effect to suppress the proliferation of experimental tumor, e.g. sarcoma 180 ascites tumor, Lewis lung carcinoma and ascites Yoshida sarcoma. It can be administered orally or parenterally. Dose: 5-150mg/day for oral administration and 0.1-30mg/day for parenteral administration.